Clinical trial
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
NCT01418001 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 31, 2011
- Completion date
- November 30, 2015
- Enrollment
- 5 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
histiocytoma/undifferentiated pleomorphic sarcoma, leiomyosarcoma, malignant fibrous, malignant peripheral nerve sheath tumor, sarcoma